Johnson & Johnson Innovative Medicine Sustainability Profile
Johnson & Johnson Innovative Medicine, a division of the renowned Johnson & Johnson family, is headquartered in the United States and operates extensively across major global regions, including Europe and Asia. Founded in 1886, the company has established itself as a leader in the pharmaceutical industry, focusing on innovative solutions in areas such as immunology, oncology, neuroscience, and infectious diseases. With a commitment to advancing healthcare, Johnson & Johnson Innovative Medicine offers a diverse portfolio of core products, including biologics and advanced therapies that are distinguished by their efficacy and safety profiles. The company has achieved significant milestones, including numerous FDA approvals and groundbreaking research initiatives, solidifying its position as a trusted name in the market. Through its dedication to innovation and patient care, Johnson & Johnson continues to make a profound impact on global health.
DitchCarbon Score
How does Johnson & Johnson Innovative Medicine's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Johnson & Johnson Innovative Medicine's score of 78 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Johnson & Johnson Innovative Medicine, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary of Johnson & Johnson, it inherits emissions data and climate commitments from its parent company. Johnson & Johnson has made significant climate commitments, including participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, which focuses on transitioning to 100% renewable energy. These initiatives reflect a robust commitment to reducing carbon emissions across its operations. While specific reduction targets for Johnson & Johnson Innovative Medicine are not detailed, the overarching goals set by Johnson & Johnson aim to achieve a 50% reduction in absolute greenhouse gas emissions by 2030, compared to a 2016 baseline. This commitment encompasses Scope 1, 2, and 3 emissions, indicating a comprehensive approach to climate action. In summary, while specific emissions data for Johnson & Johnson Innovative Medicine is not available, the company is aligned with its parent organisation's ambitious climate initiatives and targets, demonstrating a commitment to sustainability and reducing its carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 1990 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 308,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 751,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Johnson & Johnson Innovative Medicine's Industry?
How Carbon Intensive is Johnson & Johnson Innovative Medicine's Location?
Johnson & Johnson Innovative Medicine's Scope 3 Categories Breakdown
Johnson & Johnson Innovative Medicine's Scope 3 emissions, which decreased by 2% last year and increased significantly since 2011, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 72% of Scope 3 emissions.
Top Scope 3 Categories
Johnson & Johnson Innovative Medicine's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Johnson & Johnson Innovative Medicine has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
